Skip to main content
. 2021 Sep 8;49(5):2411–2429. doi: 10.1042/BST20210766

Figure 6. Glycotope and a semisynthetic vaccine conjugate from capsular polysaccharides of Group A and B Streptococcus.

Figure 6.

(A) ‘Diluted' hexasaccharide containing only the key residues necessary to elicit an immune response to Group B Streptococcus type III [54–56]. (B) Group A CPS tethered to the ScpA193 protein conferring bivalent immunity [50,51].